XML 64 R5.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Condensed Consolidated Statements Of Cash Flows (USD $)
In Thousands
6 Months Ended
Jun. 30, 2011
Jun. 30, 2010
OPERATING ACTIVITIES:    
Consolidated net income $ 135,847 $ 111,815
Adjustments to reconcile consolidated net income to net cash provided by operating activities    
Depreciation and amortization 97,739 42,955
Stock-based compensation 18,772 10,391
Amortization of debt issuance costs and premium / discount 14,345 11,564
Selling, general and administrative expenses paid in shares of common stock 129 110
Deferred income taxes 7,708 988
(Gain) loss on disposal of property, plant and equipment 211 18
Change in the fair value of acquisition-related contingent consideration (7,230) 1,120
Loss on extinguishment of debt 8,548  
Loss on auction-rate securities rights   15,659
Gain on trading securities   (15,420)
Impairment of other indefinite-lived intangibles   13,000
Changes in assets and liabilities which [provided (used)] cash:    
Accounts receivable (31,093) (30,860)
Inventories (49,202) (387)
Prepaid and other assets (2,393) (2,601)
Accounts payable 11,954 3,072
Accrued expenses 38,027 27,542
Other liabilities (9,775) (329)
Income taxes payable/receivable (19,274) (12,281)
Net cash provided by operating activities 214,313 176,356
INVESTING ACTIVITIES:    
Purchases of property, plant and equipment (23,905) (6,166)
Proceeds from sale of property, plant and equipment, net 581  
Proceeds from sales of trading securities   161,775
Acquisition, net of cash acquired (2,342,556)  
Other investments   (824)
Payment on contingent consideration (414)  
License fees (2,300)  
Net cash [(used in) provided by] investing activities (2,368,594) 154,785
FINANCING ACTIVITIES:    
Capital lease obligations repayments   (172)
Tax benefits of stock awards 5,067 452
Exercise of Endo Pharmaceuticals Holdings Inc. Stock Options 20,328 2,452
Proceeds from issuance of 2019 and 2022 Notes 900,000  
Purchase of common stock (34,701) (50,064)
Proceeds From Issuance Of Debt 2,200,000  
Principal payments on Term Loan (400,000)  
Payment on AMS Convertible Notes (273,165)  
Deferred financing fees (81,753)  
Distributions to noncontrolling interests (25,813)  
Buy-out of noncontrolling interests, net of contributions (524)  
Proceeds from other debt, net 393  
Net cash [provided by (used in)] financing activities 2,309,832 (47,332)
Effect of foreign exchange rate 104  
NET INCREASE IN CASH AND CASH EQUIVALENTS 155,655 283,809
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 466,214 708,462
CASH AND CASH EQUIVALENTS, END OF PERIOD 621,869 992,271
SUPPLEMENTAL INFORMATION:    
Cash paid for interest 24,768 9,012
Cash paid for income taxes 80,460 79,701
SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES    
Purchases of property, plant and equipment financed by capital leases 127  
Accrual for purchases of property, plant and equipment $ 2,959 $ 2,238